Rituximab, Cyclophosphamide, and Corticosteroid Combination in Difficult-to-Treat Membranous Nephropathy.
作者信息
Prabhahar Arun, Vijayakumar Niranjan Anitha, Bharati Joyita, Rani Sushma, Kumar Vinod, Nada Ritambhra, Divyaveer Smita Subhash, Rathi Manish, Singh Kohli Harbir, Jha Vivekanand, Ramachandran Raja
机构信息
Department of Nephrology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
Department of Medicine, Section Nephrology, Boston Medical Center, Boston, MA, United States.
出版信息
Indian J Nephrol. 2025 Jul-Aug;35(4):548-550. doi: 10.25259/IJN_174_2025. Epub 2025 May 16.
Abstract
摘要
相似文献
1
Rituximab, Cyclophosphamide, and Corticosteroid Combination in Difficult-to-Treat Membranous Nephropathy.
Indian J Nephrol. 2025 Jul-Aug;35(4):548-550. doi: 10.25259/IJN_174_2025. Epub 2025 May 16.
2
Immunosuppression therapy for idiopathic membranous nephropathy: systematic review with network meta-analysis.
J Nephrol. 2022 May;35(4):1159-1170. doi: 10.1007/s40620-022-01268-2. Epub 2022 Feb 23.
3
The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy.
Kidney Int. 2021 Apr;99(4):986-998. doi: 10.1016/j.kint.2020.10.014. Epub 2020 Nov 7.
4
Efficacy of low or heavy rituximab‑based protocols and comparison with seven regimens in idiopathic membranous nephropathy: a systematic review and network meta-analysis.
Int Urol Nephrol. 2023 Mar;55(3):641-651. doi: 10.1007/s11255-022-03372-5. Epub 2022 Sep 25.
5
Treatment of very high risk membranous nephropathy complicated by pulmonary embolism with glucocorticoids and rituximab: Case report.
Medicine (Baltimore). 2025 Jan 10;104(2):e41241. doi: 10.1097/MD.0000000000041241.
6
Artificial intelligence-based personalised rituximab treatment protocol in membranous nephropathy (iRITUX): protocol for a multicentre randomised control trial.
BMJ Open. 2025 Apr 2;15(4):e093920. doi: 10.1136/bmjopen-2024-093920.
7
Rituximab or Cyclophosphamide in the Treatment of Membranous Nephropathy: The RI-CYCLO Randomized Trial.
J Am Soc Nephrol. 2021 Apr;32(4):972-982. doi: 10.1681/ASN.2020071091. Epub 2021 Mar 1.
8
Economic Evaluation of Rituximab Versus Corticosteroid-Cyclophosphamide or Cyclosporine in Patients With Membranous Nephropathy in Republic of Korea.
Nephrology (Carlton). 2025 Jun;30(6):e70063. doi: 10.1111/nep.70063.
9
Urinary rituximab loss and rate of treatment failure in membranous nephropathy.
Nephrol Dial Transplant. 2025 Jul 7. doi: 10.1093/ndt/gfaf127.
10
Non-corticosteroid immunosuppressive medications for steroid-sensitive nephrotic syndrome in children.
Cochrane Database Syst Rev. 2024 Nov 8;11(11):CD002290. doi: 10.1002/14651858.CD002290.pub6.
本文引用的文献
1
Combination Therapy With Rituximab and Low-Dose Cyclophosphamide and Prednisone in Membranous Nephropathy.
Kidney Int Rep. 2024 Sep 12;9(12):3439-3445. doi: 10.1016/j.ekir.2024.08.033. eCollection 2024 Dec.
2
Combination of Rituximab, Low-Dose Cyclophosphamide, and Prednisone for Primary Membranous Nephropathy: A Case Series With Extended Follow Up.
Am J Kidney Dis. 2021 Dec;78(6):793-803. doi: 10.1053/j.ajkd.2021.04.014. Epub 2021 Jun 24.
3
Immunological remission in PLA2R-antibody-associated membranous nephropathy: cyclophosphamide versus rituximab.
Kidney Int. 2018 Apr;93(4):1016-1017. doi: 10.1016/j.kint.2017.12.019.
4
Combination therapy with rituximab, low-dose cyclophosphamide, and prednisone for idiopathic membranous nephropathy: a case series.
BMC Nephrol. 2017 Feb 1;18(1):44. doi: 10.1186/s12882-017-0459-z.
5
Tacrolimus combined with corticosteroids versus Modified Ponticelli regimen in treatment of idiopathic membranous nephropathy: Randomized control trial.
Nephrology (Carlton). 2016 Feb;21(2):139-46. doi: 10.1111/nep.12569.
6
Anti-Phospholipase A2 Receptor Antibody Titer Predicts Post-Rituximab Outcome of Membranous Nephropathy.
J Am Soc Nephrol. 2015 Oct;26(10):2545-58. doi: 10.1681/ASN.2014070640. Epub 2015 Mar 24.
Zotero 插件